Nav: Home

A defense protein that causes cancer

January 22, 2016

Cancer is caused by the growth of an abnormal cell which harbours DNA mutations, "copy errors" occurring during the DNA replication process. If these errors do take place quite regularly without having any damaging effect on the organism, some of them affect a specific part of the genome and cause the proliferation of the mutant cell, which then invades the organism. A few years ago, scientists have identified an important mutagen which lies in our own cells: APOBEC, a protein that usually functions as protecting agent against viral infection. Today, a team of Swiss and Russian scientists led by Sergey Nikolaev, geneticist at the University of Geneva (UNIGE), Switzerland, has deciphered how APOBEC takes advantage of a weakness in our DNA replication process to induce mutations in our genome. To be read in Genome Research.

APOBEC is a useful, yet dangerous, intrinsic cellular protein. Primarily meant to fight viruses, it has only the power of modifying single-stranded DNA - viral DNA being frequently single-stranded. Our double-stranded human DNA should therefore not be altered. But researchers have observed that mutations induced by APOBEC can be found in many tumorous cells, throughout the genome. How can APOBEC - which can affect only single-stranded DNA - be the cause of so many cancers in human beings? Scientists have already brought the evidence that about 20% of APOBEC mutations originate from an abnormality in the DNA, called "double-stranded breaks" which leaves, for a period of time, a part of DNA in a single-stranded state. It is this particular moment that APOBEC targets to cause multiple mutations. But if this mechanism accounts for 20% of APOBEC-related mutations, it is the mechanism governing the remaining 80% that the scientists at UNIGE and their colleagues in Moscow were able to understand.

The machinery of DNA replication

During the cell division process, the DNA must be replicated according a precise process and timing to produce two identical copies from the original DNA. The replication begins at a specific location. The separation of the two original strands and the synthesis of the new ones then result in a replication fork: the new strands are rebuilt as the fork moves along the chromosome. During DNA replication, the two strands are replicated by different mechanisms which depend on the direction of the replication fork. If one of the two strands is constructed right away, the second one cannot be reconstructed as quickly. As a result, one strand, the "leading strand", never exists as single-stranded DNA, whereas the other one, the "lagging strand", remains single-stranded for some time.

"Since we knew that APOBEC can only mutate single stranded DNA, we needed to identify in what direction the replication fork was going in order to identify the DNA regions that stay single-stranded for longer period of time, explains Sergey Nikolaev. For the first time ever, we managed to do so in human cells. We were able to identify the direction of the replication fork for about 20% of the genome, and found twice as many mutations on the lagging strand, compared with the leading strand." With this discovery, the scientists brought the evidence that APOBEC, opportunistically, takes advantage of the moment when the lagging strand remains single, therefore weaker.

Mutations that affect our most important genes

DNA replication programme is very conservative: it starts at a well-defined a point of origin. Our most important and well-protected genes replicate early, while some less important genes are replicated later on. Usually, the mutation rate is three times higher in the genome regions that replicate at a later stage.

"We were very surprised to observe that, in APOBEC cancers, the mutation rate is equally distributed in all regions. When APOBEC is involved, mutations occur early during replication, and affect important genes. These mutations tend, therefore, to be more deleterious than other kind of mutations, explains Vladimir Seplyarskiy from the Russian Academy of Sciences and fist author of this study. We do not know why yet, but APOBEC seems to act as a marker of a default in the replication mechanism in the affected cells, opening the door to an opportunistic mutagen. Indeed, the genome regions replicating early should not stay in a single-stranded state long enough for APOBEC to act. It means that something is going wrong even before APOBEC comes on the scene. " The scientists will continue their research to better understand how tumorous cells replicate their DNA differently from healthy cells.
-end-


Université de Genève

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.